Background: TOUR™ is a multicenter study designed to characterize the real-world population characteristics and clinical outcomes associated with telavancin (TLV) use through retrospective medical chart review. Telavancin is a lipoglycopeptide antibacterial active against gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). In the US, TLV is approved for hospital-acquired (HABP) and ventilator-associated [...]

Background: Procalcitonin (PCT) testing has been shown in randomized trials to decrease antibiotic exposure and be a reliable predictor of clinical response to antibiotics in lower respiratory tract infection (LRTI) and sepsis. Although studied to guide antibiotic discontinuation in LRTI and sepsis, optimal strategies for introducing PCT into “real-world” clinical use are unknown. Our study [...]